[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI3805220T1 - Policiklični karbamoilpiridonski derivati za zdravljenje HIV - Google Patents

Policiklični karbamoilpiridonski derivati za zdravljenje HIV

Info

Publication number
SI3805220T1
SI3805220T1 SI201930798T SI201930798T SI3805220T1 SI 3805220 T1 SI3805220 T1 SI 3805220T1 SI 201930798 T SI201930798 T SI 201930798T SI 201930798 T SI201930798 T SI 201930798T SI 3805220 T1 SI3805220 T1 SI 3805220T1
Authority
SI
Slovenia
Prior art keywords
hiv
treatment
polycyclic carbamoylpyridone
carbamoylpyridone derivatives
derivatives
Prior art date
Application number
SI201930798T
Other languages
English (en)
Inventor
Yoshiyuki Taoda
Yuto UNOH
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Publication of SI3805220T1 publication Critical patent/SI3805220T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201930798T 2018-05-31 2019-05-30 Policiklični karbamoilpiridonski derivati za zdravljenje HIV SI3805220T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018104156 2018-05-31
PCT/JP2019/021446 WO2019230858A1 (ja) 2018-05-31 2019-05-30 多環性カルバモイルピリドン誘導体
EP19810498.6A EP3805220B1 (en) 2018-05-31 2019-05-30 Polycyclic carbamoylpyridone derivatives for the treatment of hiv

Publications (1)

Publication Number Publication Date
SI3805220T1 true SI3805220T1 (sl) 2024-10-30

Family

ID=68698918

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930798T SI3805220T1 (sl) 2018-05-31 2019-05-30 Policiklični karbamoilpiridonski derivati za zdravljenje HIV

Country Status (30)

Country Link
US (2) US11649236B2 (sl)
EP (2) EP4257137A3 (sl)
JP (2) JP7328962B2 (sl)
KR (1) KR20210015922A (sl)
CN (2) CN117327072A (sl)
AR (1) AR115455A1 (sl)
AU (2) AU2019277548B2 (sl)
BR (1) BR112020024077A2 (sl)
CA (1) CA3102063A1 (sl)
CL (1) CL2020003002A1 (sl)
CO (1) CO2020014294A2 (sl)
CR (2) CR20230571A (sl)
DK (1) DK3805220T3 (sl)
DO (1) DOP2020000221A (sl)
EA (1) EA202092921A1 (sl)
ES (1) ES2984245T3 (sl)
FI (1) FI3805220T3 (sl)
IL (2) IL313474A (sl)
LT (1) LT3805220T (sl)
MA (1) MA52795A (sl)
MD (1) MD3805220T2 (sl)
MX (2) MX2020012176A (sl)
PE (1) PE20210477A1 (sl)
PH (1) PH12020552000A1 (sl)
PT (1) PT3805220T (sl)
RS (1) RS65891B1 (sl)
SG (1) SG11202011382PA (sl)
SI (1) SI3805220T1 (sl)
WO (1) WO2019230858A1 (sl)
ZA (1) ZA202007567B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
JPWO2021107065A1 (sl) * 2019-11-28 2021-06-03
EP4066839A4 (en) * 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED IN THAT IT COMPRISES A COMBINATION OF AN INTEGRASE INHIBITOR AND AN ANTI-HIV AGENT
CN115151545A (zh) 2020-02-24 2022-10-04 吉利德科学公司 用于治疗hiv感染的四环化合物
JP7407976B2 (ja) * 2020-05-21 2024-01-04 シーセン ファーマシューティカル カンパニー リミテッド 縮合環誘導体及びその薬学的用途
KR20230044252A (ko) * 2020-07-27 2023-04-03 머크 샤프 앤드 돔 엘엘씨 인플루엔자를 치료 또는 예방하기 위한 폴리시클릭 캡-의존성 엔도뉴클레아제 억제제
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
WO2023006087A1 (zh) * 2021-07-30 2023-02-02 南京明德新药研发有限公司 大环吡啶酮类化合物及其应用
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024061257A1 (zh) * 2022-09-20 2024-03-28 吉斯凯(苏州)制药有限公司 多环氮杂环酮类化合物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
PL377354A1 (pl) 2002-12-27 2006-01-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4H-pirydo[1,2-a]pirymidyny i związki pokrewne użyteczne jako inhibitory integrazy HIV
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
EP3284519A1 (en) 2005-04-28 2018-02-21 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
CA2626956A1 (en) * 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
CN102858771A (zh) 2010-02-26 2013-01-02 日本烟草产业株式会社 1,3,4,8-四氢-2H-吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的用途
JP5766690B2 (ja) 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
CN103974957A (zh) 2011-10-12 2014-08-06 盐野义制药株式会社 具有整合酶抑制活性的多环吡啶酮衍生物
EP2931730B1 (en) * 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
KR102120875B1 (ko) 2012-12-21 2020-06-09 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
HUE036384T2 (hu) 2013-05-17 2018-07-30 Merck Sharp & Dohme Fúzionált triciklusos heterociklikus vegyületek mint HIV integráz inhibitorok
EP3008044B1 (en) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
CA2916993C (en) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (sl) 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
CA2924829C (en) 2013-09-27 2019-10-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015199167A1 (ja) 2014-06-25 2015-12-30 日本たばこ産業株式会社 置換されたスピロピリド［１，２－ａ］ピラジン誘導体の製造方法および中間体
JPWO2016027879A1 (ja) 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
US10150780B2 (en) 2014-12-09 2018-12-11 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as HIV integrase inhibitors
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016154527A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
EP3277691B1 (en) 2015-04-02 2019-01-30 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
EP3377065B1 (en) 2015-11-17 2022-05-18 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
EP3548031B1 (en) 2016-12-02 2023-07-19 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
US11413292B2 (en) 2018-02-15 2022-08-16 Merck, Sharp & Dohme LLC Tricyclic heterocycle compounds useful as HIV integrase inhibitors
JP2021522254A (ja) 2018-04-27 2021-08-30 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
IL279050B1 (en) 2018-05-31 2024-08-01 Shionogi & Co Consequence of polycyclic pyridone
EP3801543B1 (en) 2018-06-05 2024-09-11 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
CN108957755B (zh) 2018-07-27 2021-04-30 京东方科技集团股份有限公司 一种显示组件及其控制方法、平视显示器及汽车
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba

Also Published As

Publication number Publication date
ZA202007567B (en) 2022-04-28
EP4257137A2 (en) 2023-10-11
BR112020024077A2 (pt) 2021-02-09
CO2020014294A2 (es) 2020-12-21
MA52795A (fr) 2021-04-14
ES2984245T3 (es) 2024-10-29
MD3805220T2 (ro) 2024-10-31
IL279051A (en) 2021-01-31
EP3805220A1 (en) 2021-04-14
RS65891B1 (sr) 2024-09-30
DOP2020000221A (es) 2021-03-15
US11649236B2 (en) 2023-05-16
CR20200644A (es) 2021-02-05
MX2020012176A (es) 2021-01-29
IL279051B1 (en) 2024-09-01
MX2023010377A (es) 2023-09-12
CR20230571A (es) 2024-01-22
EP4257137A3 (en) 2023-11-01
AU2019277548A1 (en) 2021-01-14
LT3805220T (lt) 2024-08-26
DK3805220T3 (da) 2024-08-26
AU2019277548B2 (en) 2023-12-14
PE20210477A1 (es) 2021-03-11
CL2020003002A1 (es) 2021-04-16
FI3805220T3 (fi) 2024-08-30
CN112513042B (zh) 2023-09-29
PT3805220T (pt) 2024-08-16
KR20210015922A (ko) 2021-02-10
PH12020552000A1 (en) 2021-09-27
US20230227454A1 (en) 2023-07-20
IL313474A (en) 2024-08-01
AR115455A1 (es) 2021-01-20
EP3805220A4 (en) 2022-01-05
CN117327072A (zh) 2024-01-02
JP7328962B2 (ja) 2023-08-17
CN112513042A (zh) 2021-03-16
US20210122751A1 (en) 2021-04-29
CA3102063A1 (en) 2019-12-05
EP3805220B1 (en) 2024-07-31
JPWO2019230858A1 (ja) 2021-06-24
EA202092921A1 (ru) 2021-04-07
JP2023145723A (ja) 2023-10-11
US20240352015A1 (en) 2024-10-24
SG11202011382PA (en) 2020-12-30
AU2024200783A1 (en) 2024-02-29
WO2019230858A1 (ja) 2019-12-05

Similar Documents

Publication Publication Date Title
RS65891B1 (sr) Policiklični karbamoilpiridonski derivati za lečenje hiv-a
IL276917A (en) A process for the preparation of alubixivet
IL268737A (en) Processes for the preparation of benzodiapine derivatives
IL275482A (en) Asketamine for the treatment of depression
EP3618829A4 (en) QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER ASSOCIATED DISORDERS
EP3634417A4 (en) QUINAZOLINE-PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
HK1258276A1 (zh) 用於治療hiv的化合物和組合
IL283948A (en) Methods for treating depression
IL260465B (en) A process for preparing an antibody-rifamycin conjugate
EP3580185A4 (en) SLUDGE TREATMENT PROCESS
IL286000A (en) Asketamine for the treatment of depression
EP3405183A4 (en) ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
HK1257272A1 (zh) 治療hiv的工具
EP3416645A4 (en) COMPOUNDS FOR THE TREATMENT OF MALARIA
LT3765440T (lt) N-alkil-nitratoetilnitraminų gamybos būdas
IL281254A (en) A process for the preparation of lanbatinib
EP3877361C0 (en) PROCESS FOR PREPARING ARYLSULFONYLPROPENENITRILE
EP3507277B8 (en) Hydroxynorketamine derivatives for the treatment of disorders
PL3599256T3 (pl) Sposób wytwarzania poliorganosiloksanów
IL274560A (en) A process for the preparation of raltagravir
HUP1800278A2 (en) Process for the preparation of boc-linagliptin
GB201901130D0 (en) Formulation for the treatment of tendinopathies
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
IL260405A (en) None-abusive derivatives of ritalin
EP3638224A4 (en) METHOD OF TREATMENT OF LEPTOMENING DISEASE